Apoptotic Vesicles as Tumor Vaccine

ImmunotherapyVol. 8, No. 1 EditorialApoptotic vesicles as tumor vaccineSophie K Horrevorts, Juan J Garcia-Vallejo, Sandra J van Vliet, Arjan A van de Loosdrecht, Yvette van Kooyk & Tanja D de GruijlSophie K Horrevorts Department of Molecular Cell Biology & Immunology, VU University Medical Center, Amsterdam, The Netherlands, Juan J Garcia-Vallejo Department of Molecular Cell Biology & Immunology, VU University Medical Center, Amsterdam, The Netherlands, Sandra J van Vliet Department of Molecular Cell Biology & Immunology, VU University Medical Center, Amsterdam, The Netherlands, Arjan A van de Loosdrecht Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands, Yvette van Kooyk Department of Molecular Cell Biology & Immunology, VU University Medical Center, Amsterdam, The Netherlands & Tanja D de Gruijl*Author for correspondence: E-mail Address: TD.deGruijl@vumc.nl Medical Oncology, VU University Medical Center, Amsterdam, The NetherlandsPublished Online:7 Dec 2015https://doi.org/10.2217/imt.15.96AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: antigensapoptosiscancer treatmentvaccinevesiclesReferences1 Kenter GG, Welters MJP, Valentijn ARPM et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N. Engl. J. Med. 361, 1838–1847 (2009).Crossref, Medline, CAS, Google Scholar2 Gilboa E. The makings of a tumor rejection antigen. Immunity 11, 263–270 (1999).Crossref, Medline, CAS, Google Scholar3 Rosenberg SA, Yang JC, Sherry RM et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 17, 4550–4558 (2011).Crossref, Medline, CAS, Google Scholar4 Le DT, Uram JN, Wang H et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509–2520 (2015).Crossref, Medline, CAS, Google Scholar5 Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science 348(6230), 69–74 (2015).Crossref, Medline, CAS, Google Scholar6 Lawrence MS, Stojanov P, Polak P et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214–218 (2013).Crossref, Medline, CAS, Google Scholar7 Kokhaei P, Choudhury A, Mahdian R et al. Apoptotic tumor cells are superior to tumor cell lysate, and tumor cell RNA in induction of autologous T cell response in B-CLL. Leuk. Off. J. Leuk. Soc. Am. Leuk. Res. Fund UK 18, 1810–1815 (2004).Crossref, Medline, CAS, Google Scholar8 Hayashi T, Hideshima T, Akiyama M et al. Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes. Blood 102, 1435–1442 (2003).Crossref, Medline, CAS, Google Scholar9 Ruben JM, Van Den Ancker W, Bontkes HJ et al. Apoptotic blebs from leukemic cells as a preferred source of tumor-associated antigen for dendritic cell-based vaccines. Cancer Immunol. Immunother. 63, 335–345 (2014).Crossref, Medline, CAS, Google Scholar10 Ruben JM, Bontkes HJ, Westers TM et al. In situ loading of skin dendritic cells with apoptotic bleb-derived antigens for the induction of tumor-directed immunity. OncoImmunology 4, 1–10 (2014).Google Scholar11 Yáñez-Mó M, Siljander PR, Andreu Z et al. Biological properties of extracellular vesicles and their physiological functions. J. Extracell. Vesicles 4, 1–60 (2015).Crossref, Google Scholar12 Théry C, Ostrowski M, Segura E. Membrane vesicles as conveyors of immune responses. Nat. Rev. Immunol. 9, 581–593 (2009).Crossref, Medline, CAS, Google Scholar13 Kalra H, Simpson RJ, Ji H et al. Vesiclepedia: a compendium for extracellular vesicles with continuous community annotation. PLoS Biol. 10, 8–12 (2012).Crossref, Google Scholar14 Fransen JH, Hilbrands LB, Ruben J et al. Mouse dendritic cells matured by ingestion of apoptotic blebs induce T cells to produce interleukin-17. Arthritis Rheum. 60, 2304–2313 (2009).Crossref, Medline, CAS, Google Scholar15 Liu K, Iyoda T, Saternus M, Kimura Y, Inaba K, Steinman RM. Immune tolerance after delivery of dying cells to dendritic cells in situ. J. Exp. Med. 196, 1091–1097 (2002).Crossref, Medline, CAS, Google Scholar16 Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat. Rev. Cancer 12, 860–875 (2012).Crossref, Medline, CAS, Google Scholar17 Spisek R, Charalambous A, Mazumder A, Vesole DH, Jagannath S, Dhodapkar MV. Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications. Blood 109, 4839–4845 (2007).Crossref, Medline, CAS, Google Scholar18 Bilyy RO, Shkandina T, Tomin A et al. Macrophages discriminate glycosylation patterns of apoptotic cell-derived microparticles. J. Biol. Chem. 287, 496–503 (2012).Crossref, Medline, CAS, Google Scholar19 Meesmann HM, Fehr E-M, Kierschke S et al. Decrease of sialic acid residues as an eat-me signal on the surface of apoptotic lymphocytes. J. Cell Sci. 123, 3347–3356 (2010).Crossref, Medline, CAS, Google Scholar20 Fehres CM, Kalay H, Bruijns SCM et al. Cross-presentation through langerin and DC-SIGN targeting requires different formulations of glycan-modified antigens. J. Control. Release 203, 67–76 (2015).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetailsCited ByInducing Endoplasmic Reticulum Stress to Expose Immunogens: A DNA Tetrahedron Nanoregulator for Enhanced Immunotherapy16 September 2020 | Advanced Functional Materials, Vol. 30, No. 48Expression levels of a gene signature in hiPSC associated with lung adenocarcinoma stem cells and its capability in eliciting specific antitumor immune‐response in a humanized mice model20 April 2020 | Thoracic Cancer, Vol. 11, No. 6 Vol. 8, No. 1 Follow us on social media for the latest updates Metrics Downloaded 138 times History Published online 7 December 2015 Published in print January 2016 Information© Future Medicine LtdKeywordsantigensapoptosiscancer treatmentvaccinevesiclesFinancial & competing interests disclosureSK Horrevorts was supported by ERC-Advanced-Glycotreat-339977. JJ Garcia-Vallejo was supported by ERC-Advanced-Glycotreat-339977and the CCA (Cancer center Amsterdam). SJ van Vliet was supported by the Dutch Cancer Society (KWF, VU2014–6779). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download